IT8922768A0 - Composti attivi come inibitori dell'enzima hmg-coa reduttasi - Google Patents

Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Info

Publication number
IT8922768A0
IT8922768A0 IT22768A IT2276889A IT8922768A0 IT 8922768 A0 IT8922768 A0 IT 8922768A0 IT 22768 A IT22768 A IT 22768A IT 2276889 A IT2276889 A IT 2276889A IT 8922768 A0 IT8922768 A0 IT 8922768A0
Authority
IT
Italy
Prior art keywords
inhibitors
active compounds
coa reductase
enzyme hmg
hmg
Prior art date
Application number
IT22768A
Other languages
English (en)
Other versions
IT1237793B (it
Inventor
Giorgio Bertolini
Cesare Casagrande
Francesco Santangelo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to IT02276889A priority Critical patent/IT1237793B/it
Publication of IT8922768A0 publication Critical patent/IT8922768A0/it
Priority to EP19900123761 priority patent/EP0433842A3/en
Priority to US07/626,762 priority patent/US5081136A/en
Priority to JP2418293A priority patent/JPH04210682A/ja
Application granted granted Critical
Publication of IT1237793B publication Critical patent/IT1237793B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT02276889A 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi IT1237793B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EP19900123761 EP0433842A3 (en) 1989-12-21 1990-12-11 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
US07/626,762 US5081136A (en) 1989-12-21 1990-12-13 1,2,3-triazole compounds active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
JP2418293A JPH04210682A (ja) 1989-12-21 1990-12-20 酵素ＨＭＧ−ＣｏＡレダクターゼの抑制剤として活性な化合物ならびに該化合物を含む医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Publications (2)

Publication Number Publication Date
IT8922768A0 true IT8922768A0 (it) 1989-12-21
IT1237793B IT1237793B (it) 1993-06-17

Family

ID=11200250

Family Applications (1)

Application Number Title Priority Date Filing Date
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Country Status (4)

Country Link
US (1) US5081136A (it)
EP (1) EP0433842A3 (it)
JP (1) JPH04210682A (it)
IT (1) IT1237793B (it)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1037616C (zh) * 1993-07-15 1998-03-04 中国科学院兰州化学物理研究所 多功能润滑油添加剂
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US7939105B2 (en) * 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
EP1216037A2 (en) * 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
EP1267914B2 (en) 2000-02-04 2013-11-06 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
ES2310676T3 (es) 2002-12-20 2009-01-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP2006523613A (ja) * 2002-12-20 2006-10-19 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ 徐放性医薬投与のための被覆粒子
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
EP1848424B1 (en) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
WO2006087630A2 (en) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
EP1890691A2 (en) 2005-05-31 2008-02-27 Mylan Laboratories, Inc Compositions comrising nebivolol
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
WO2007146229A2 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2057987B1 (en) 2006-08-30 2015-03-04 Kyushu University, National University Corporation Pharmaceutical composition containing statin-encapsulated nanoparticle
EP1921072A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
EP2114151A4 (en) * 2007-03-01 2010-03-17 Concourse Health Sciences Llc INOSITOL NIACINATE ISOMERS AND USES THEREOF
JP5271350B2 (ja) 2007-04-18 2013-08-21 テシス バイオサイエンス， インコーポレイテッド 糖尿病に関連するバイオマーカーおよびその使用方法
WO2009102761A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
CA2800520A1 (en) 2010-04-08 2011-10-13 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
CN103189370B (zh) 2010-11-09 2015-07-08 霍夫曼-拉罗奇有限公司 作为gaba受体用配体的三唑衍生物
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
EP2879666B1 (en) 2012-08-01 2020-04-08 Tavakoli, Zahra Free flowing, frozen compositions comprising a therapeutic agent
SG11201507751YA (en) 2013-03-21 2015-10-29 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
TW201720427A (zh) 2015-10-27 2017-06-16 優普順藥物股份有限公司 局部麻醉劑之持續釋放調配物
KR101777634B1 (ko) * 2016-01-18 2017-09-12 연성정밀화학(주) 3-((2s,5s)-4-메틸렌-5-(3-옥소프로필)테트라히드로퓨란-2-일)프로판올 유도체의 제조방법 및 이를 위한 중간체
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP4126858A1 (en) 2020-03-26 2023-02-08 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61502467A (ja) * 1984-06-22 1986-10-30 サンド・アクチエンゲゼルシヤフト メバロノラクトンのピラゾ−ル同族体およびその誘導体、それらの製造方法ならびに用途
US4808607A (en) * 1985-05-22 1989-02-28 Sandoz Pharm. Corp. Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte

Also Published As

Publication number Publication date
IT1237793B (it) 1993-06-17
US5081136A (en) 1992-01-14
JPH04210682A (ja) 1992-07-31
EP0433842A3 (en) 1992-01-08
EP0433842A2 (en) 1991-06-26

Similar Documents

Publication Publication Date Title
IT1237793B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3770345D1 (de) Inhibitoren von hmg-coa-reduktase.
NO882218L (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
NO180718C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive mercaptoacetylamidderivater
NO931795L (no) Dobbeltvirkende inhibitorer
MC2313A1 (fr) Inhibiteurs d'enzymes
NO304649B1 (no) AnalogifremgangsmÕte for fremstilling av farmakologisk aktive pyrimidinforb
MX9203768A (es) Inhibidores novedosos de reductasa 3-hidroxi-metilglutaril-coenzima a.
IT1237792B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
NO882219D0 (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
MX9100998A (es) Novedosos inhibidores de escualen sintetasa
ZA886468B (en) Novel hmg-coa reductase inhibitors
ITMI921854A1 (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina
NO901422D0 (no) Fremgangsmaate for fremstilling av alfa-glucosidase-inhibitorer.
MA21068A1 (fr) Procede de preparation d'une composition a base d'inhibiteur de l'enzyme de conversion de l'angiotensine .
DE69025817D1 (de) 3-Keto-HMG-CoA Reduktase-Inhibitoren
CA2183314A1 (en) Novel 2-Substituted Indane-2-Mercaptoacetylamide Disulfide Derivatives Useful as Inhibitors of Enkephalinase and Ace
NO921673D0 (no) Inhibitor av laminin-neurittaktiverende aktivitet
NO923862L (no) Inhibitorer for hmg-coa-reduktase
IE861455L (en) Preparation of hmg-coa reductase inhibitors
SU1277584A1 (ru) 1,1-Ди-[2-(2-фурил)4-оксохиназолинил-3]-этилиден, проявляющий противовоспалительную и анальгезирующую активность
IE861739L (en) Hmg-coa reductase inhibitors
ITVE920028A0 (it) Procedimento di preparazione di non tessuti adesivi
FI103114B (fi) Menetelmä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten s akkariinijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
0001 Granted